Starget Pharma is pioneering the development of Smart Targeted Radioligands (STRs) aimed at enhancing precision oncology for challenging cancers. Their innovative approach focuses on the targeted delivery of radiation directly to tumoral and metastatic cells, significantly reducing collateral damage to healthy tissues. This is achieved through their proprietary peptide-based backbone dynamics technology platform, which transforms peptides into next-generation radiopharmaceuticals. By leveraging advanced backbone cyclization techniques, Starget Pharma enhances the molecular diversity of peptides, facilitating the rapid identification of effective radioligand candidates. This technology is designed to optimize the stability, affinity, and biodistribution of these targeted therapies, ultimately broadening the therapeutic window for patients with limited treatment options.

In addition to STRs, Starget Pharma emphasizes the importance of targeted molecular radiotherapy, a clinically validated approach that combines diagnostic and therapeutic capabilities. This method utilizes a radionuclide and a molecular ligand to deliver targeted radiation, allowing for precise treatment of cancerous lesions. The company’s expertise in molecular engineering enables the design of radioligands that effectively navigate and deliver radiation to cancer sites. Starget Pharma's commitment to advancing cancer care is reflected in their mission to accelerate the discovery and development of novel targeted radioligands, positioning them as a key player in the evolving landscape of cancer treatment.

United States

Starget Pharma is a clinical stage company developing a pipeline of radioligand therapy programs generated using its proprietary Backbone Dynamics peptide platform that leverages backbone cyclic innovations and in-silico AI to rapidly design highly specific Smart Targeted Radioligands (STRs) that deliver focused radiation for the imaging and treatment of hard-to-treat cancers.

Starget Pharma

Company Details